Glaucoma is chronic, degenerative disorder that damages the eye's optic nerve, may result in vision loss and blindness. Factors such, high prevalence of glaucoma, technological advancement in diagnostic technique, rising treatment awareness are driving the market growth of glaucoma therapeutics globally.
The report titled Glaucoma Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall glaucoma therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global glaucoma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global glaucoma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global glaucoma therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.
Glaucoma is a chronic, degenerative condition that damages the eye's optic nerve, resulting in vision loss and blindness. Factors such as increase in prevalence of eye disorders, significant unmet medical needs and rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in the year 2016, prostaglandin analogs was largest revenue generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combination such as Dorzolamide and Timolol, Latanoprost and Timolol, Brimonidine and Timolol are widely used in market. Patient adherence is more for fixed-dose combination as they reduces the risk of medication washout and also decrease daily topical preservative load. It is observed that beta blockers is second major revenue generating segment, they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increase in heart rate and blood pressure negatively impacting the growth of glaucoma therapeutic market.
In the base year 2021, North America dominated the glaucoma therapeutics market in terms of revenue and it is anticipated that it will show steady growth during forecast period of 2022-2030. Factors such as rising geriatric population, upsurge in funding by government agencies and private organizations in healthcare system, increasing incidence of eye disorders, improved diagnostic techniques drive the growth of glaucoma therapeutics market in North America. Europe is the second largest revenue generating regional market for glaucoma therapeutics. U.K., Germany and France are major revenue contributing countries in Europe. It is observed that Middle East and Africa is hold smallest market share and it is anticipated that it will show sluggish market growth during forecast period. Comparatively lower cost of treatment medication hinder the market growth of glaucoma therapeutics in Middle East and Africa. Currently, Asia Pacific is not a major revenue generating segment. However, it is anticipated that it will experience a significant growth during the forecast period. Factors such as increasing population, continuous economic development and developing healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Glaucoma Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall glaucoma therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global glaucoma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global glaucoma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global glaucoma therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.
Glaucoma is a chronic, degenerative condition that damages the eye's optic nerve, resulting in vision loss and blindness. Factors such as increase in prevalence of eye disorders, significant unmet medical needs and rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in the year 2016, prostaglandin analogs was largest revenue generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combination such as Dorzolamide and Timolol, Latanoprost and Timolol, Brimonidine and Timolol are widely used in market. Patient adherence is more for fixed-dose combination as they reduces the risk of medication washout and also decrease daily topical preservative load. It is observed that beta blockers is second major revenue generating segment, they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increase in heart rate and blood pressure negatively impacting the growth of glaucoma therapeutic market.
In the base year 2021, North America dominated the glaucoma therapeutics market in terms of revenue and it is anticipated that it will show steady growth during forecast period of 2022-2030. Factors such as rising geriatric population, upsurge in funding by government agencies and private organizations in healthcare system, increasing incidence of eye disorders, improved diagnostic techniques drive the growth of glaucoma therapeutics market in North America. Europe is the second largest revenue generating regional market for glaucoma therapeutics. U.K., Germany and France are major revenue contributing countries in Europe. It is observed that Middle East and Africa is hold smallest market share and it is anticipated that it will show sluggish market growth during forecast period. Comparatively lower cost of treatment medication hinder the market growth of glaucoma therapeutics in Middle East and Africa. Currently, Asia Pacific is not a major revenue generating segment. However, it is anticipated that it will experience a significant growth during the forecast period. Factors such as increasing population, continuous economic development and developing healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Glaucoma Therapeutics market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Glaucoma Therapeutics market and their expected impact during the forecast period.
Market Segmentation
Drug Class
- Prostaglandins Analogs
- Beta Blockers
- Alpha-adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Fixed-dose Combinations
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Glaucoma Therapeutics market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Glaucoma Therapeutics market?
- Which is the largest regional market for Glaucoma Therapeutics market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Glaucoma Therapeutics market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Glaucoma Therapeutics market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Glaucoma Therapeutics Market
2.2. Global Glaucoma Therapeutics Market, By Drug Class, 2021 (US$ Million)
2.3. Global Glaucoma Therapeutics Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Glaucoma Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Glaucoma Therapeutics Market Vendors
3.2. Strategies Adopted by Glaucoma Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Glaucoma Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Glaucoma Therapeutics Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Prostaglandins Analogs
5.3.2. Beta Blockers
5.3.3. Alpha-adrenergic Agonists
5.3.4. Carbonic Anhydrase Inhibitors
5.3.5. Fixed-dose Combinations
6. North America Glaucoma Therapeutics Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
6.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7. UK and European Union Glaucoma Therapeutics Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8. Asia Pacific Glaucoma Therapeutics Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
9. Latin America Glaucoma Therapeutics Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
9.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
10. Middle East and Africa Glaucoma Therapeutics Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
10.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
11. Company Profile
11.1. Aerie Pharmaceuticals
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Akorn, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Allergan plc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bausch & Lomb Incorporated
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Inotek Pharmaceuticals
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Merck & Co., Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Pfizer Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Santen Pharmaceuticals Co. Ltd
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Teva Pharmaceuticals
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Glaucoma Therapeutics Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Glaucoma Therapeutics Market: Quality Assurance
Figure 5 Global Glaucoma Therapeutics Market, By Drug Class, 2021
Figure 6 Global Glaucoma Therapeutics Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Glaucoma Therapeutics Market, 2021
Figure 8 Market Positioning of Key Glaucoma Therapeutics Market Players, 2021
Figure 9 Global Glaucoma Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Glaucoma Therapeutics Market, By Drug Class, 2021 Vs 2030, %
Figure 11 U.S. Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 12 Canada Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 14 UK Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 15 Germany Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 16 Spain Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 17 Italy Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 18 France Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 20 China Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 21 Japan Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 22 India Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 23 Australia Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 24 South Korea Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 26 Brazil Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 27 Mexico Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 29 GCC Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 30 Africa Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 2 North America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 3 U.S. Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 4 Canada Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 5 Rest of North America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 6 UK and European Union Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 7 UK Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 8 Germany Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 9 Spain Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 10 Italy Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 11 France Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 12 Rest of Europe Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 13 Asia Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 14 China Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 15 Japan Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 16 India Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 17 Australia Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 18 South Korea Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 19 Latin America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 20 Brazil Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 21 Mexico Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 22 Rest of Latin America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 23 Middle East and Africa Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 24 GCC Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 25 Africa Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Companies Mentioned
- Aerie Pharmaceuticals
- Akorn Inc.
- Allergan plc.
- Bausch & Lomb Incorporated
- Inotek Pharmaceuticals
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Santen Pharmaceuticals Co. Ltd
- Teva Pharmaceuticals .
